C
Challenger Limited
+ HoldingTLX
+0.50%
3M Return
$11.290
-0.085 (-0.75%)At close
Loading chart…
- High
- 11.470
- Open
- 11.470
- VWAP
- 11.32
- Vol
- 88.53K
- Mkt Cap
- —
- Low
- 11.207
- Amount
- 1.00M
- EV/EBITDA, TTM
- 19.11
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
AI analysis of Telix Pharmaceuticals Ltd (TLX)
holdTelix Pharmaceuticals is currently a hold. The stock closed at $11.29, which is below the analyst price target of $22 from Citi, indicating potential upside. However, the RSI is at 42.57, suggesting it is nearing oversold territory, and the forward P/E ratio is high at 156.25, indicating the stock may be overvalued. The main risk is the downgrade from RBC Capital, which reflects concerns about valuation despite strong revenue growth.
Valuation Metrics
The current forward P/E ratio for Telix Pharmaceuticals Ltd (TLX) is 156.25, compared to its 5-year average forward P/E of 720.21.
Whales holding TLX
Events Timeline
News
9.508-20NASDAQ.COMTelix Pharmaceuticals Reports 22% Revenue Growth in Half-Year Results
9.508-20NewsfilterTelix Pharmaceuticals Reports Strong H1 2026 Financial Results with Significant Growth
9.507-30GlobenewswireTelix Pharmaceuticals Announces Half-Year Financial Results Date
- 9.507-30Newsfilter
Telix Pharmaceuticals Announces Half-Year Financial Results Date
- 2.007-21Newsfilter
Telix Announces ProstACT SELECT Study Results Confirming TLX591-Tx Efficacy
TLX FAQ — answered by Alphio AI
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx. It operates in the Healthcare sector.
Telix Pharmaceuticals is currently a hold. The stock closed at $11.29, which is below the analyst price target of $22 from Citi, indicating potential upside. However, the RSI is at 42.57, suggesting it is nearing oversold territory, and the forward P/E ratio is high at 156.25, indicating the stock may be overvalued. The main risk is the downgrade from RBC Capital, which reflects concerns about valuation despite strong revenue growth.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.